OCP-TAP approves Adtran’s OSA 5400 TimeCard™ for precise, resilient data center timing
28.9.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced that the Open Compute Project (OCP) Time Appliance Project (TAP) has approved its OSA 5400 TimeCard™ for data center timing and synchronization. The pluggable device injects Adtran’s Oscilloquartz timing technology into any white box server, solving key challenges in the transition to virtualized environments. The OCP-TAP’s endorsement means data center operators leveraging the OSA 5400 TimeCard™ to synchronize COTS hardware can be assured of precise, reliable and robust timing as they move to more cost-efficient and scalable network architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928894327/en/
The OSA 5400 TimeCard™ represents a simple route to accurate, reliable and robust data center timing. (Photo: Business Wire)
“We’re pleased to be able to announce that Adtran’s OSA 5400 TimeCard™ now supports the OCP-TAP driver. It’s an important milestone in our collective quest to advance robust and accurate timing solutions for distributed system use cases. By meeting our framework’s specifications, Adtran is helping us drive standardization and interoperability, accelerating the industry’s shift to open, standardized hardware,” said Ahmad Byagowi, TAP project leader at OCP-TAP. “This pluggable solution represents a simple route to accurate, reliable and robust data center timing. We believe that solutions like the OSA 5400 TimeCard™ will play a pivotal role in advancing the next generation of scalable and resilient infrastructure.”
Enabling data center operators to efficiently host the most demanding time-sensitive applications, Adtran’s OSA 5400 TimeCard™ plugs into any free PCIe slot to turn a standard COTS server into a precise PTP grandmaster clock or NTP server. With multiple oscillator options, the solution ensures accurate timing even during extended periods of GNSS disturbances. In combination with Adtran’s Ensemble Sync Director, the OSA 5400 TimeCard™ provides operational teams with a comprehensive, unified view of their entire timing infrastructure. This enables them to easily manage all elements of their timing network, enhancing control and reliability. What’s more, the OSA 5400 TimeCard™ has been developed to align fully with the IEEE P3335 standardization, ensuring adaptability and underscoring Adtran’s commitment to industry advancement in a cohesive digital ecosystem.
“We’re proud that our OSA 5400 TimeCard™ has been validated by OCP-TAP. This card brings our 74 years of expertise in timing and synchronization to standard servers, going beyond the TAP specifications to provide a scalable, fully featured timing solution in a compact half-size PCIe card. It offers a major boost for data center operators looking to embrace open, disaggregated hardware, especially where timing is vital and space is limited. Our OSA 5400 TimeCard™ ensures seamless, efficient operation of mission-critical and time-sensitive applications,” commented Igal Pinhasov, VP of PLM at Oscilloquartz, Adtran. “As the industry progresses towards agile, cost-effective data center environments, our pluggable timing technology will play a defining role in shaping future architectures.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230928894327/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
